| name | ata-pituitary-apoplexy-gc-until-diagnosis |
| description | Administers glucocorticoid coverage in patients with pituitary apoplexy to prevent adrenal crisis while awaiting definitive laboratory diagnosis. Triggers include managing a pituitary apoplexy patient needing glucocorticoid coverage until laboratory confirmation of pituitary function. |
Administer glucocorticoid therapy until laboratory diagnosis established in pituitary apoplexy
STEP 1 — Gather Information
Collect clinical history (sudden severe headache, visual field defects, ophthalmoplegia, altered mental status, nausea/vomiting), vital signs, basic metabolic panel (serum sodium, potassium, glucose), serum cortisol and ACTH, full pituitary hormone panel (TSH, free T4, LH/FSH, testosterone/estradiol, prolactin, IGF-1), and emergent pituitary MRI. If pituitary apoplexy is suspected based on presentation and imaging, proceed to step 2.
STEP 2 — Rule In / Rule Out
Rule in pituitary apoplexy using acute neuro-ophthalmic symptoms and pituitary hemorrhage/infarction on MRI; rule out other causes of acute headache (e.g., subarachnoid hemorrhage, meningitis). If pituitary apoplexy is confirmed or highly suspected, go to step 3; otherwise, consider alternative diagnoses and discontinue empiric glucocorticoid coverage.
STEP 3 — Classify or Stratify
Classify stress level as minor-to-moderate (based on hemodynamic stability, absence of major surgical stress, or septic shock) to determine hydrocortisone dose range of 25–75 mg per 24 hours; if major stress is present (e.g., impending surgery, shock), consider higher dosing per section 3.15. Select the appropriate hydrocortisone dosing regimen.
STEP 4 — Decide
Administer hydrocortisone as a total daily dose of 25–75 mg in divided doses (highest dose in the morning) via intravenous or oral route, and continue until laboratory diagnosis of pituitary function is established (confirming deficiencies) and the patient maintains normal pituitary function on replacement; then transition to maintenance glucocorticoid therapy.
Clinical Guardrails / Mimics / Pitfalls
Do not delay glucocorticoid administration awaiting laboratory results; avoid fludrocortisone in secondary adrenal insufficiency; monitor for hyperglycemia, fluid overload, and signs of over-treatment; avoid dexamethasone in pregnancy; ensure stress-dose glucocorticoids for any invasive procedures or stressors.
Concrete Clinical Example
A 58‑year‑old woman presents with sudden severe headache, bifrontal vision loss, and nausea. MRI shows pituitary hemorrhage with suprasellar extension. She is hypotensive (BP 88/50) and hyponatremic (Na 128 mmol/L). Empiric hydrocortisone 50 mg IV bolus followed by 50 mg continuous infusion over 24 h is started. Labs drawn show low morning cortisol and low ACTH. After 24 h she is clinically improving; glucocorticoid therapy is continued until formal pituitary panel confirms deficiencies and she is stable on replacement.
Source: Hormonal Replacement in Hypopituitarism in Adults: An Endocrine Society Clinical Practice Guideline, Endocrine Society, 2016, DOI:10.1210/jc.2016-2118
